Breaking News Instant updates and real-time market news.

AMGN

Amgen

$176.25

-2.44 (-1.37%)

09:04
12/07/17
12/07
09:04
12/07/17
09:04

Amgen says new data to be presented at ASH 2017

Amgen announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved medicines and investigational immuno-oncology agents from the company's robust hematology portfolio and pipeline will be presented at the 59th American Society of Hematology Annual Meeting & Exposition in Atlanta, Dec. 9-12, 2017. The breadth and depth of data to be presented at ASH highlight Amgen's commitment to advancing treatment options for patients with some of the most difficult-to-treat blood cancers and disorders. Notably at ASH, positive overall survival results from the Phase 3 ASPIRE trial will be detailed for the first time in an oral presentation, which showed the addition of KYPROLIS to lenalidomide and dexamethasone significantly extended OS versus lenalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The safety data from ASPIRE was consistent with the known safety profile of KYPROLIS.

  • 18

    Jan

  • 03

    Feb

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN Amgen
$176.25

-2.44 (-1.37%)

10/31/17
PIPR
10/31/17
NO CHANGE
Target $170
PIPR
Overweight
Piper says Amgen more credible biosimilar threat to Alexion in Europe
Piper Jaffray analyst Christopher Raymond believes Amgen's (AMGN) threat of a biosimilar alternative to Alexion Pharmaceuticals' (ALXN) Soliris may be more credible and near-term than he previously thought. The analyst highlights a Phase 3 study recently listed in the European Union's Clinical Trials Registry, which was authorized in August, as well as evidence of Amgen's active opposition to Alexion's intellectual property extension efforts in Europe. He reminds investors that two-thirds of Soliris' revenue is outside the U.S. Given this new evidence, "it would appear the real battleground may be Europe," Raymond tells investors in a research note. He keeps an Overweight rating on Alexion with a $170 price target. He views the company as well positioned to defend itself against Amgen.
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold from Buy at Argus
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold at Argus on secular slowdown in sales of top drugs
As reported earlier, Argus analyst David Toung downgraded Amgen to Hold from Buy, noting a "secular" slowdown in sales of the company's top three products - Enbrel, Neulasta and Aranesp. Toung says the sales of growth prospects Prolia, Kyprolis and Repatha are not yet large enough to offset the declines in the three established drugs which face generic competition after losing patent protection. The analyst notes that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal challenges.
11/29/17
PIPR
11/29/17
NO CHANGE
Target $190
PIPR
Overweight
Piper still bullish on Amgen after management meeting
Piper Jaffray analyst Christopher Raymond says he remains bullish on Amgen shares after hosting the company's management at his firm's healthcare conference. The analyst sees near-term pipeline catalysts from Amgen's immuno-oncology approach, which he sees coming more into focus, Repatha label expansion, Parsabiv launch and Aimovig approval/launch next year. Raymond maintains an Overweight rating on the shares with a $190 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/15/18
08/15
12:17
08/15/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/15/18
08/15
12:16
08/15/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.78

-3.02 (-1.06%)

12:11
08/15/18
08/15
12:11
08/15/18
12:11
Technical Analysis
Technical Take: SPDR S&P 500 ETF off lows at midday »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.78

-3.02 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$22.53

-0.635 (-2.74%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Recommendations
Vodafone analyst commentary  »

Vodafone added as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$335.00

-12.6 (-3.62%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Recommendations
Tesla analyst commentary  »

Tesla moved to Not Rated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

LB

L Brands

$31.63

-1.1 (-3.36%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Options
Bullish longer-term option play in L Brands ahead of earnings next week »

Bullish longer-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

AMP

Ameriprise

$137.45

-1.23 (-0.89%)

12:10
08/15/18
08/15
12:10
08/15/18
12:10
Hot Stocks
Ameriprise to pay $4.5M for not safeguarding client assets »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHN

Schnitzer Steel

$25.95

-2.3 (-8.14%)

12:09
08/15/18
08/15
12:09
08/15/18
12:09
Conference/Events
Schnitzer Steel management to meet with KeyBanc »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 22

    Aug

TSLA

Tesla

$334.50

-13.1 (-3.77%)

, GS

Goldman Sachs

$229.91

0.38 (0.17%)

12:08
08/15/18
08/15
12:08
08/15/18
12:08
Periodicals
Breaking Periodicals news story on Tesla, Goldman Sachs »

Goldman Sachs to act as…

TSLA

Tesla

$334.50

-13.1 (-3.77%)

GS

Goldman Sachs

$229.91

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CRC

California Resources

$28.77

-3.32 (-10.35%)

12:05
08/15/18
08/15
12:05
08/15/18
12:05
Options
California Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

TSLA

Tesla

$334.80

-12.8 (-3.68%)

12:04
08/15/18
08/15
12:04
08/15/18
12:04
Periodicals
Silver Lake would like to participate in Tesla deal, DealBook says »

Silver Lake, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ATVI

Activision Blizzard

$68.98

-2.31 (-3.24%)

, SNE

Sony

$53.46

-0.83 (-1.53%)

12:02
08/15/18
08/15
12:02
08/15/18
12:02
Hot Stocks
Activision's Call of Duty World League Championship comes to Ohio this week »

Activision Blizzard…

ATVI

Activision Blizzard

$68.98

-2.31 (-3.24%)

SNE

Sony

$53.46

-0.83 (-1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

PFGC

Performance Food Group

$33.30

-4.3 (-11.44%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Performance Food Group falls -11.4% »

Performance Food Group is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

CANG

Cango

$8.90

-1.6 (-15.24%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Cango falls -12.0% »

Cango is down -12.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$36.24

-5.63 (-13.45%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Macy's falls -13.4% »

Macy's is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 17

    Sep

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$10.22

1.31 (14.70%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF rises 14.6% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMG

KMG Chemicals

$77.39

10.61 (15.89%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
KMG Chemicals rises 15.7% »

KMG Chemicals is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$30.29

5.67 (23.03%)

12:00
08/15/18
08/15
12:00
08/15/18
12:00
Hot Stocks
Canopy Growth rises 22.9% »

Canopy Growth is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

12:00
08/15/18
08/15
12:00
08/15/18
12:00
General news
Short-covering on the S&P 500 ahead of 2.8k »

Short-covering on the…

M

Macy's

$36.27

-5.6 (-13.37%)

, STZ

Constellation Brands, also tag STZ.B

$202.15

-19.62 (-8.85%)

11:57
08/15/18
08/15
11:57
08/15/18
11:57
General news
Fly Intel: Wall Street's top stories at midday »

Stocks opened deep in…

M

Macy's

$36.27

-5.6 (-13.37%)

STZ

Constellation Brands, also tag STZ.B

$202.15

-19.62 (-8.85%)

CGC

Canopy Growth

$30.21

5.59 (22.71%)

KMG

KMG Chemicals

$77.30

10.52 (15.75%)

CCMP

Cabot Microelectronics

$111.65

-9.67 (-7.97%)

PETQ

PetIQ

$34.99

6.73 (23.81%)

FANG

Diamondback Energy

$120.33

-13.42 (-10.03%)

EGN

Energen

$76.24

3.09 (4.22%)

CASA

Casa Systems

$12.20

-3.425 (-21.93%)

STZ.B

Constellation Brands

$212.44

-8.54 (-3.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

  • 15

    Aug

  • 21

    Aug

  • 22

    Aug

  • 11

    Sep

  • 17

    Sep

  • 25

    Oct

  • 28

    Oct

APC

Anadarko

$64.41

-2.56 (-3.82%)

11:55
08/15/18
08/15
11:55
08/15/18
11:55
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRVS

Corvus Pharmaceuticals

$9.47

0.44 (4.87%)

11:55
08/15/18
08/15
11:55
08/15/18
11:55
Upgrade
Corvus Pharmaceuticals rating change  »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXS

BancorpSouth

$34.20

-0.2 (-0.58%)

11:45
08/15/18
08/15
11:45
08/15/18
11:45
Conference/Events
BancorpSouth management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 23

    Aug

BXS

BancorpSouth

$34.20

-0.2 (-0.58%)

11:45
08/15/18
08/15
11:45
08/15/18
11:45
Conference/Events
BancorpSouth management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 23

    Aug

ALRM

Alarm.com

$50.63

0.02 (0.04%)

11:43
08/15/18
08/15
11:43
08/15/18
11:43
Conference/Events
Alarm.com management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 22

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.